This is the current release of the guideline.

The use of chemotherapy sensitivity and resistance assays to select chemotherapeutic agents for individual patients is not recommended outside of the clinical trial setting. Oncologists should make chemotherapy treatment recommendations on the basis of published reports of clinical trials and a patient’s health status and treatment preferences. Selection of chemotherapeutic agents on the basis of results of chemotherapy sensitivity and resistance assays (CSRAs) is not warranted based on the current body of evidence. Because the in vitro analytic strategy has potential importance, participation in clinical trials evaluating these technologies remains a priority.

None provided

The type of evidence supporting each recommendation is not specifically stated. The recommendations are based on a critical review of the current scientific and clinical information.

Not applicable: The guideline was not adapted from another source.

2004 Aug 2 (published online ahead of print)

American Society of Clinical Oncology - Medical Specialty Society

American Society of Clinical Oncology (ASCO)

American Society of Clinical Oncology Working Group on Chemotherapy Sensitivity and Resistance Assays

Authors: Deborah Schrag; Harinder S. Garewal; Harold J. Burstein; David J. Samson; Daniel D. Von Hoff; Mark R. Somerfield

Working Group Members: Deborah Schrag, MD (Co-chair), Memorial Sloan-Kettering Cancer Center; Daniel D. Von Hoff, MD (Co-chair), Arizona Cancer Center; Jaffer Ajani, MD, UT M.D. Anderson Cancer Center; Al B. Benson III, MD, Northwestern University Feinberg School of Medicine; Harold J. Burstein, MD, PhD, Dana-Farber Cancer Institute; Rowan T. Chlebowski, MD, PhD, Harbor UCLA Medical Center; Harinder S. Garewal, MD, PhD, Arizona Cancer Center; Anne Hamburger, PhD, Cancer Center-University of Maryland; Axel Hanauske, MD, PhD, Sections Medical Oncology, Germany; Lawrence B. Holt Jr, MD, FACP, Coastal Cancer Center; Samir N. Khleif, MD, NCI Naval Hospital Bethesda; Gary H. Lyman, MD, University of Rochester Medical Center; Cheryl Perkins, Susan G. Komen Foundation; John Sandbach, MD, Texas Oncology Cancer Center; James A. Talcott, MD, Massachusetts General Hospital; Peter H. Wiernik, MD, OLM Cancer Center; David J. Samson (Ex-Officio), Blue Cross Blue Shield Association

All Working Group members complied with the American Society of Clinical Oncology (ASCO) policy on conflict of interest, which required disclosure of any interest (financial or otherwise) that might be construed as constituting an actual, potential, or apparent conflict. Members completed ASCO’s disclosure form and were asked at the face-to-face meeting to report ties to companies developing products that might be affected by promulgation of the technology assessment report. Information was requested regarding employment, stock ownership, honoraria, research funding, expert testimony, and membership on company advisory committees. One member of the original Working Group chose to resign based on self-identified perceived conflict. No other limiting conflicts were identified among the Working Group members.

The following contributors have indicated a financial interest. No conflict exists for drugs or devices used in a study if they are not being evaluated as part of the investigation. Acted as a consultant within the last 2 years: Axel Hanauske, Eli Lilly & Co, Hoffman-La Roche, iOnGen; Rowan T. Chlebowski, AstraZeneca, Novartis, Aventis, Eli Lilly & Co. Performed contract work within the last 2 years: Axel Hanauske, Eli Lilly & Co, Hoffman-La Roche. Served as an officer or member of the Board of a company: Anne Hamburger, Biocell, Analytical Biosystems Corp. Received more than $2,000 a year from a company for either of the last 2 years: Axel Hanauske, Eli Lilly & Co; Jaffer Ajani, Novartis, Aventis, Sanofi, Taiho; Rowan T. Chlebowski, AstraZeneca, Novartis, Aventis, Eli Lilly & Co.

This is the current release of the guideline.

This NGC summary was completed by ECRI on September 24, 2004. The information was verified by the guideline developer on September 24, 2004.

This summary is based on the original guideline, which is subject to the American Society of Clinical Oncology's copyright restrictions.